BR112013020539A2 - sais de diamínio fenotiazina e seu uso - Google Patents

sais de diamínio fenotiazina e seu uso

Info

Publication number
BR112013020539A2
BR112013020539A2 BR112013020539A BR112013020539A BR112013020539A2 BR 112013020539 A2 BR112013020539 A2 BR 112013020539A2 BR 112013020539 A BR112013020539 A BR 112013020539A BR 112013020539 A BR112013020539 A BR 112013020539A BR 112013020539 A2 BR112013020539 A2 BR 112013020539A2
Authority
BR
Brazil
Prior art keywords
alkyl
independently selected
halogenated
alkenyl
salts
Prior art date
Application number
BR112013020539A
Other languages
English (en)
Inventor
Ishaq Antsham
alan wood Barry
Robert Harrington Charles
Michel Wischik Claude
Marshall Colin
Williamson Craig
Horsley David
Peter Sinclair James
Elizabeth Rickard Janet
Mervyn David Storey John
Ahmad Khan Karrar
Simpson Michael
Clunas Scott
Craven Baddeley Thomas
Sze Loh Yin
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of BR112013020539A2 publication Critical patent/BR112013020539A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/20[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0052Visible light
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35Naphthalene sulfonic acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

sais de diamínio fenotiazina e seu uso a presente invenção refere-se a compostos da fórmula (i) geral: em que: cada um de r^ 1^ e r^ 9^ é independentemente selecionado a partir de: -h, alquila c~ 1-4~, e alquenila c~ 2-4~ e alquila c~ 1-4~ halogenada; cada um de r^ 3na^ e r^ 3nb^ é independentemente selecionado a partir de : -h, alquila c~ 1-4~, alquenila c~ 2-4~ e alquila c~ 1-4~ halogenada; cada um de r^ 7na^ e r^ 7nb^ é independentemente selecionado a partir de : -h, alquila c~ 1-4~, alquenila c~ 2-4~ e alquila c~ 1-4~ halogenada; e em que: cada um de r^ a^ e r^ b^ é independemente selecionado a partir de: alquila c~ 1-4~, alquila c~ 1-4~ halogenada, e arila c~ 6-10~; ou r^ a^ e r^ b^ são ligados para formar um grupo selecionado a partir de: alquileno c~ 1-6~ e arileno c~ 6-10~; e sais farmaceuticamente aceitáveis destes, que são úteis no tratamento, por exemplo, da doença de alzheimer. em outros aspectos, a invenção também se refere a novas formulações de sais 3,7 -diamino-10h- fenotiazínio.
BR112013020539A 2011-02-11 2011-08-15 sais de diamínio fenotiazina e seu uso BR112013020539A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2011010600 2011-02-11
US201161485880P 2011-05-13 2011-05-13
PCT/GB2011/001221 WO2012107706A1 (en) 2011-02-11 2011-08-15 Phenothiazine diaminium salts and their use

Publications (1)

Publication Number Publication Date
BR112013020539A2 true BR112013020539A2 (pt) 2017-09-26

Family

ID=44532939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020539A BR112013020539A2 (pt) 2011-02-11 2011-08-15 sais de diamínio fenotiazina e seu uso

Country Status (26)

Country Link
US (5) US9283230B2 (pt)
EP (1) EP2673266B1 (pt)
JP (2) JP5898701B2 (pt)
KR (1) KR101888713B1 (pt)
CN (2) CN105853439A (pt)
AR (2) AR082699A1 (pt)
AU (1) AU2011358840B2 (pt)
BR (1) BR112013020539A2 (pt)
CA (1) CA2827027C (pt)
CY (1) CY1118102T1 (pt)
DK (1) DK2673266T3 (pt)
EA (1) EA025033B1 (pt)
ES (1) ES2594703T3 (pt)
HK (1) HK1186738A1 (pt)
HR (1) HRP20161291T1 (pt)
HU (1) HUE031633T2 (pt)
IL (2) IL227736A (pt)
LT (1) LT2673266T (pt)
MY (1) MY165906A (pt)
PL (1) PL2673266T3 (pt)
PT (1) PT2673266T (pt)
RS (1) RS55237B1 (pt)
SG (1) SG192666A1 (pt)
SI (1) SI2673266T1 (pt)
SM (1) SMT201600389B (pt)
WO (1) WO2012107706A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478058T3 (de) 2006-03-29 2010-09-15 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
CN102718730B (zh) 2006-07-11 2018-06-05 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
KR101741235B1 (ko) * 2013-08-15 2017-05-29 유파마 피티와이 엘티디 디아미노페노티아지니움 화합물을 정제하는 방법
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
EP3140384B1 (en) * 2014-05-06 2024-02-14 Milliken & Company Laundry care compositions
BR112017021283A2 (pt) * 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3,7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
CN106046027B (zh) * 2016-06-30 2019-03-05 广东工业大学 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用
KR20230058533A (ko) * 2016-07-25 2023-05-03 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP6958860B2 (ja) 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
CA3106152A1 (en) * 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
JP7401531B2 (ja) 2018-09-05 2023-12-19 ゲンティング タークス ダイアグノースティク センター エスディエヌ ビーエイチディ 神経変性疾患のためのネットワーク法
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN116056724A (zh) * 2020-05-05 2023-05-02 维斯塔实验室有限公司 用于治疗covid-19的甲基硫堇鎓化合物
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
CA3181388A1 (en) 2020-05-05 2021-11-11 Wista Laboratories Ltd. Methylthioninium compounds for use in the treatment of hypoxemia
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
KR102396975B1 (ko) 2022-01-11 2022-05-12 이덕형 페이스 리프팅기 및 이를 위한 동작 방법
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023202464A1 (zh) * 2022-04-19 2023-10-26 英科隆生物技术(杭州)有限公司 一种电子媒介体的提纯方法
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (pt) 1957-07-17
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ATE438716T1 (de) 1991-12-06 2009-08-15 Max Planck Gesellschaft Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
EP0778773A1 (en) 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
US6030767A (en) 1997-01-21 2000-02-29 The American National Red Cross Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
AU2001229619A1 (en) 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
EP1687286A1 (en) 2003-11-28 2006-08-09 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
AU2005286235C1 (en) 2004-09-23 2013-08-22 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC)
WO2006091728A2 (en) 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
WO2007056439A1 (en) 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
ATE478058T3 (de) * 2006-03-29 2010-09-15 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
DK2004155T3 (en) * 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CA2645919C (en) 2006-03-29 2016-05-31 Wista Laboratories Ltd. Thioninium compounds and their use
CN102718730B (zh) 2006-07-11 2018-06-05 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
PL2167095T3 (pl) 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
MY161656A (en) * 2007-10-03 2017-04-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines

Also Published As

Publication number Publication date
DK2673266T3 (en) 2016-10-24
EA201391158A8 (ru) 2016-05-31
MY165906A (en) 2018-05-18
SG192666A1 (en) 2013-09-30
US20200246350A1 (en) 2020-08-06
AR121016A2 (es) 2022-04-06
ES2594703T3 (es) 2016-12-22
WO2012107706A1 (en) 2012-08-16
HUE031633T2 (en) 2017-07-28
CA2827027A1 (en) 2012-08-16
US9283230B2 (en) 2016-03-15
JP5898701B2 (ja) 2016-04-13
EA025033B1 (ru) 2016-11-30
IL249056B (en) 2019-09-26
CY1118102T1 (el) 2017-06-28
JP6093890B2 (ja) 2017-03-08
JP2016138117A (ja) 2016-08-04
US20160237048A1 (en) 2016-08-18
IL227736A (en) 2017-07-31
CN103649061B (zh) 2016-04-20
PT2673266T (pt) 2016-10-07
KR101888713B1 (ko) 2018-08-14
PL2673266T3 (pl) 2017-01-31
CA2827027C (en) 2019-06-04
JP2014505095A (ja) 2014-02-27
CN103649061A (zh) 2014-03-19
US20190046537A1 (en) 2019-02-14
AR082699A1 (es) 2012-12-26
CN105853439A (zh) 2016-08-17
WO2012107706A8 (en) 2013-09-19
US11180464B2 (en) 2021-11-23
US20130315992A1 (en) 2013-11-28
HRP20161291T1 (hr) 2016-11-18
US20220098161A1 (en) 2022-03-31
EP2673266A1 (en) 2013-12-18
HK1186738A1 (zh) 2014-03-21
US9907804B2 (en) 2018-03-06
KR20140007428A (ko) 2014-01-17
IL227736A0 (en) 2013-09-30
SMT201600389B (it) 2017-01-10
US10864216B2 (en) 2020-12-15
IL249056A0 (en) 2017-01-31
RS55237B1 (sr) 2017-02-28
AU2011358840A1 (en) 2013-09-12
EP2673266B1 (en) 2016-07-27
SI2673266T1 (sl) 2016-11-30
LT2673266T (lt) 2016-10-10
AU2011358840B2 (en) 2017-05-04
EA201391158A1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
BR112013020539A2 (pt) sais de diamínio fenotiazina e seu uso
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
BR112014001801A2 (pt) indazóis
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
BR112013029240A2 (pt) derivados deuterados do ivacaftor
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BRPI0519287A2 (pt) derivados de amida
AR072249A1 (es) Inhibidores de amida hidrolasa de acido graso. usos. metodos.
BR112015014714A2 (pt) compostos carbamoilpiridona policíclicos e seu uso farmacêutico
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
BR112018016932A2 (pt) processo para a preparação de ácido 4 -fenil -5 -alcoxicarbonil -2 -tiazol -2 -il -1,4 -diidropirimidin -6 -il[metil] -3 -oxo -5,6,8,8a -tetrahidro -1h -imidazo[1,5 -a]pirazin -2 -il] -carboxil acid
BR112015004529A8 (pt) alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
CY1117792T1 (el) Ανταγωνιστες toy trpv4
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
BR112014001642A2 (pt) fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas e uso das mesmas como medicamento
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
EA201792071A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
MX2016001095A (es) Sales de dasatinib en forma cristalina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: WISTA LABORATORIES LTD. (SG)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]